Related Experiment Video
Updated: Jun 15, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Treatment of Extraneural Metastases of Myxopapillary Ependymomas With Dose-Dense Temozolomide and Lapatinib
Devon C Riegel1, Ekokobe Fonkem1, Jennifer M Connelly1
1Neurology, Medical College of Wisconsin, Milwaukee, USA.
Abstract:
Myxopapillary ependymomas (MPEs) are rare tumors of the central nervous system, and outcomes are generally worse with recurrent disease. These tumors can rarely metastasize outside the neuraxis. We present a case of a 35-year-old female with a history of MPEs who developed extraneural metastases 11 years after her initial gross total resection. Sites of metastases included multiple bilateral intrapulmonary and pleural-based masses with pleural effusion and a pelvic mass. The patient was treated with dose-dense TMZ and lapatinib and had a mixed radiographic response after 12 cycles of treatment. This is the first known case of extraneural metastases of MPEs to demonstrate a radiographic response to dose-dense TMZ and lapatinib. This case presentation discusses the need to establish optimal treatment of extraneural ependymal metastases, duration of treatment, and strategy for the management of recurrent diseases.
Insights
This case study details a rare instance of myxopapillary ependymoma (MPE) extraneural metastasis. The patient showed a mixed radiographic response to dose-dense TMZ and lapatinib, offering new treatment insights.
Area of Science:
- Neuro-oncology
- Pathology
Background:
- Myxopapillary ependymomas (MPEs) are rare central nervous system tumors.
- Recurrent MPEs have poorer prognoses, and extraneural metastasis is exceptionally uncommon.

